Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.
Cox. Holly D HD; Miller. Geoff D GD; Eichner. Daniel D
Key Findings
- BPC‑157 remains stable in urine for at least four days, indicating it persists in the body after use.
- A weak cation exchange solid‑phase extraction method can detect BPC‑157 in urine with a limit of detection of 0.1 ng/mL, precision under 20%, and excellent linearity (R² = 0.998).
- Including measurement of a BPC‑157 metabolite alongside the parent peptide improves the specificity of the detection method.
Practical Outcomes
- For biohackers, this means urine testing can confirm whether BPC‑157 has been taken and how long it stays in the system. The peptide’s multi‑day stability suggests dosing intervals could be spaced out, but the study does not provide any dosing or efficacy guidance.
Summary
Scientists figured out how to reliably spot the peptide BPC‑157 in urine and showed it stays stable there for several days. They created a sensitive test that can detect tiny amounts (0.1 ng/mL) and also looks for a breakdown product to make the result more specific.
Abstract
A new peptide, body protecting compound (BPC), BPC 157, and a variant of mechano-growth factor (MGF), MGF R23H, were identified in confiscated vials. BPC 157 has the amino acid sequence, GEPPPGKPADDAGLV, and is currently under investigation for the promotion of healing and recovery in a variety of tissues. In vitro metabolism experiments in plasma demonstrate that MGF R23H has good stability and should be detectable in urine, while BPC 157 forms a stable metabolite that should be detectable in urine. A weak cation exchange solid phase extraction method was validated for detection of BPC 157 in urine. The method has a limit of detection of 0.1 ng/mL, precision of less than 20%, and good linearity, r<sup>2</sup> 0.998. BPC 157 was stable in urine for at least 4 days. The specificity of the method is improved by measurement of a potential BPC metabolite along with the parent peptide. Copyright © 2016 John Wiley & Sons, Ltd.
Study Information
pubmed
2017
2017-02-10T00:00:00.000Z
10.1002/dta.2152
9
27